Association of pre-surgery to pre-radiotherapy lymphocyte counts ratio with disease-free survival in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy

被引:9
作者
Xu, Hongen [1 ]
You, Guangxian [2 ]
Zhang, Minjun [1 ,3 ]
Song, Tao [1 ]
Zhang, Haibo [1 ]
Yang, Jia [1 ]
Jia, Yongshi [1 ]
Tang, Jianming [1 ]
Liang, Xiaodong [1 ]
机构
[1] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Radiat Oncol, Canc Ctr,Peoples Hosp, 158 Shangtang Rd, Hangzhou 310014, Zhejiang, Peoples R China
[2] Taizhou Canc Hosp, Dept Radiat Oncol, Taizhou 317502, Peoples R China
[3] Bengbu Med Coll, Grad Dept, 2600 Donghai Ave, Bengbu 233000, Peoples R China
关键词
Rectal cancer; Lymphocyte counts; Disease-free survival; Chemoradiotherapy; ACUTE HEMATOLOGIC TOXICITY; DOSIMETRIC PARAMETERS; CERVICAL-CANCER; LYMPHOPENIA; CHEMORADIATION; CHEMOTHERAPY; PREDICTORS; MARKER; TUMOR;
D O I
10.1186/s12957-019-1747-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Colorectal cancer is the fourth most common cancer globally and neoadjuvant concurrent chemoradiotherapy (nCRT) and surgery are the standard treatments for locally advanced colorectal carcinoma. This study investigated the association between dynamic changes in absolute lymphocyte counts (ALCs) and disease-free survival (DFS) in rectal cancer patients receiving nCRT and identified factors associated with these changes. Methods We retrospectively examined 34 patients with locally advanced rectal cancer who received nCRT followed by surgery and adjuvant chemotherapy. The association between ALCs and DFS and that between ALCs and downstaging were analyzed and potential clinical- and treatment-related factors related to dynamic changes in ALCs were subsequently evaluated. The patient eligibility criteria were as follows: pathologically confirmed rectal adenocarcinoma, clinical stages II-III, >= 18 years of age, and so on. Pre-RTL was defined as ALCs obtained before the initiation of nCRT and pre-SL was defined as ALCs obtained before surgery. We measured pre-SL to pre-RTL ratio (pre-SLR), DFS, and ALCs. Results The median ALC declined significantly during nCRT. A lower pre-SLR was associated with poorer DFS with statistical significance in Kaplan-Meier (p = 0.007), univariate regression (hazard ratio [HR] = 6.287, 95% confidence interval [CI] 1.374-28.781, p = 0.018), and multivariable regression (HR = 7.347, 95% CI 1.595-33.850, p = 0.011) analyses. Neither patient characteristics nor treatment-related factors were related to downstaging. The pelvic bone marrow (PBM) volume receiving at least 30 Gy (V30) was significantly associated with pre-SLR in the univariate (HR = 5.760, 95% CI 1.317-25.187, p = 0.020) and multivariable (HR = 5.760, 95% CI 1.317-25.187, p = 0.020) regression analyses. Limitations Our study had several limitations. The sample size was small and the study was performed in a selected population, which may limit the generalization of the findings. Conclusions Radiotherapy had a profound impact on the change in ALCs. A lower pre-SLR was significantly associated with poorer DFS in rectal cancer patients receiving nCRT. The V30 of PBM was a predictor of pre-SLR.
引用
收藏
页数:7
相关论文
共 35 条
  • [31] An Interval >7 Weeks between Neoadjuvant Therapy and Surgery Improves Pathologic Complete Response and Disease–Free Survival in Patients with Locally Advanced Rectal Cancer
    Hagit Tulchinsky
    Einat Shmueli
    Arie Figer
    Joseph M. Klausner
    Micha Rabau
    Annals of Surgical Oncology, 2008, 15 : 2661 - 2667
  • [32] Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation
    Díaz-González, JA
    Calvo, FA
    Cortés, J
    García-Sabrido, JL
    Gómez-Espí, M
    del Valle, E
    Muñoz-Jiménez, F
    Alvarez, E
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (04): : 1122 - 1128
  • [33] Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients
    Guo-Chun Zhang
    Xue-Ke Qian
    Zi-Bai Guo
    Chong-Yang Ren
    Meng Yao
    Xue-Rui Li
    Kun Wang
    Jian Zu
    Ning Liao
    Medical Oncology, 2012, 29 : 3222 - 3231
  • [34] Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis
    Markovina, Stephanie
    Youssef, Fady
    Roy, Amit
    Aggarwal, Sonya
    Khwaja, Shariq
    DeWees, Todd
    Tan, Benjamin
    Hunt, Steven
    Myerson, Robert J.
    Chang, Daniel T.
    Parikh, Parag J.
    Olsen, Jeffrey R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : 417 - 426
  • [35] Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series
    Sastre, Javier
    Jose Serrano, Juan
    Fernandez, Cristina
    Ramirez, Carmen
    Ortega, Luis
    Garcia-Paredes, Beatriz
    Corona, Juan
    Alfonso, Rosario
    Cordoba, Sofia
    Diaz-Rubio, Eduardo
    CLINICAL COLORECTAL CANCER, 2016, 15 (02) : 128 - 134